3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Unknown
1
Suspended
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
21
Neoplasms
6
Neoplasm Metastasis
5
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hereditary Sensory and Autonomic Neuropathies
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Breast Diseases
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Refractory to Standard Therapy
1
Solid Tumor, Adult
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Rare Tumor
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm, Residual
1
Melanoma
1
Medulloblastoma
1
Malignant Female Reproductive System Neoplasm
1
Lung Neoplasms
1
Interventions
pembrolizumab
25
Cisplatin
17
Carboplatin
13
Radiotherapy
12
Cetuximab
9
Blood Specimen Collection
9
Docetaxel
8
Paclitaxel
7
Fluorouracil
7
Drug Therapy
7
toripalimab
6
tislelizumab
4
nimotuzumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiation
4
Chemoradiotherapy
4
fludarabine
3
Surgical Procedures, Operative
3
Standard of Care
3
Radiotherapy, Intensity-Modulated
3
Cyclophosphamide
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
cemiplimab
2
avelumab
2
X-Rays
2
Tocopherols
2
Tiragolumab
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Head and Neck Neoplasms
×
palbociclib
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled